Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
Dublin, Ireland-based Shire Pharmaceuticals has issued a voluntary recall on three lots of VPRIV, a long-term intravenous enzyme replacement therapy for patients with type 1 Gaucher disease, due to stainless steel and barium sulfate particulate matter found in a few…
Stamford, Conn.-based Purdue Pharma, the manufacturer of OxyContin, announced successful results from a stage three clinical trial on its hydrocodone drug designed to prevent misuse and abuse of the drug.
Waukesha County, Wis.-based ProHealth Care has selected Mundelein, Ill.-based Medline as its exclusive medical and surgical supply distribution partner.
The U.S. Food and Drug Administration approved Herstal, Belgium-based STX-Med to market Cefaly, the first medical device offering preventative treatment for migraines.
Dallas-based MD Buyline has released a set of product enhancements for its Buyline Purchased Services Program that allows PSP subscribers more customized interaction with their purchased services.
Phoenix-based SharedClarity, a subsidiary of Minneapolis-based UnitedHealth Group, has signed agreements with Medtronic and Abbott Laboratories to buy the majority of its heart stents from the device companies at highly discounted prices for its 135 network hospitals, according to a…
Resorbable screws made from pure silk may provide greater benefits in bone fracture fixation than the traditional metal alloy fixation systems, according to an article in Nature Communications.
New York-based Pfizer has issued a recall on three lots of Effexor XR and Greenstone LLC-branded Venlafaxine HC1 capsules because a pharmacist reported finding a Tikosyn (dofetilide) capsule in one bottle of Effexor XR.
The Valencia, Calif.-based Alfred Mann Foundation has launched a medical device start-up company called Medallion Therapeutics, based in the Minneapolis/St. Paul area, according to a news release.
During the first two months of 2014, $4.06 billion were placed in healthcare exchange traded funds in the U.S., largely due to the biotechnology and pharmaceutical sectors, according to a Bloomberg report.